Search
NUC B1000
go.drugbank.com/drugs/DB05242ExperimentalOn January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its experimental treatment for chronic Hepatitis B virus (HBV) infection. … NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid
Secobarbital
go.drugbank.com/drugs/DB00418ApprovedVet approvedIt is commonly known as quinalbarbitone in the United Kingdom.
Neostigmine
go.drugbank.com/drugs/DB01400ApprovedInvestigationalVet approvedA cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine.
Synonyms: 3-Trimethylammoniumphenyl N,N-dimethylcarbamateMitoquinone
go.drugbank.com/drugs/DB05063InvestigationalMitochondrial dysfunction also has been shown to represent an early critical event in the pathogenesis of the sporadic form of Parkinson's disease. … In 2004, a genomic study of hereditary early-onset Parkinson's disease demonstrated a direct molecular link between mitochondrial dysfunction and the pathogenesis of Parkinson's disease.
Mirococept
go.drugbank.com/drugs/DB06492ExperimentalIt consists of the first three short consensus domains of human complement receptor 1 (CR1), manufactured in recombinant bacteria and modified with a membrane-targeting amphiphilic peptide based on the … It is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation
Aspartame
go.drugbank.com/drugs/DB00168InvestigationalNutraceuticalFlavoring agent sweeter than sugar, metabolized as phenylalanine and aspartic acid.
Synonyms: 3-Amino-N-(alpha-carboxyphenethyl)succinamic acid N-methyl ester, 3-Amino-N-(α-carboxyphenethyl)succinamic acid N-methyl esterCategories: Compounds used in a research, industrial, or household settingFasinumab
go.drugbank.com/drugs/DB12157Investigational[A241190] It has since been recognized for its role in nociceptive signaling transduction and has thus become an attractive target in the treatment of chronic pain conditions. … NSAIDs and/or opioids) in this patient population.[A241165] NGF was first discovered in the 1950s[A241180] and was the first neurotrophic factor to be identified and biochemically characterized.
NOX-700
go.drugbank.com/drugs/DB05464ExperimentalNOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes). … In animal studies, NOX-700 lowered serum glucose, improved glucose tolerance, and reduced the percentage of total glycated hemoglobin.
MIP-1095 I-131
go.drugbank.com/drugs/DB14978InvestigationalMIP-1095 I-131 is under investigation in clinical trial NCT03030885 (Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)).
Mebendazole
go.drugbank.com/drugs/DB00643ApprovedInvestigationalVet approvedA benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. [PubChem]